Sarepta Therapeutics Announces Second Quarter 2018 Financial Results and Recent Corporate Developments

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Sarepta Therapeutics Announces Second Quarter 2018 Financial Results and Recent Corporate Developments

Sarepta Therapeutics (SRPT) Gains 8.5% Off the Open

August 9, 2018 9:40 AM EDT

Sarepta Therapeutics (NASDAQ: SRPT) gains 8.5% off the open following results, update.

... More

Baird Reiterates Outperform on Sarepta Therapeutics (SRPT)

August 9, 2018 9:06 AM EDT

Baird reiterated an Outperform rating and $202.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) following a quarterly update. Exondys51 sales come in ahead of expectations at $73.5M vs. consensus estimate of $71.0M, a $8.9 sequential increase over 1Q18. Sales continue to track towards the... More

Sarepta Therapeutics (SRPT) Posts Smaller Q2 Loss on Higher Revenues

August 8, 2018 4:21 PM EDT

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.43), $0.46 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $73.5 million versus the consensus estimate of $71.59 million.

We are very pleased to report another strong quarter, marrying our vision to become one of the most meaningful precision genetic medicine companies globally with a strong focus on execution against both our near- and long-term range goals, stated Doug Ingram, Sareptas president and chief... More